ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a private placement financing. The company has entered into a purchase agreement with existing institutional and accredited investors to issue and sell approximately $3.0 million of warrants through a private investment in public equity $(PIPE)$ financing. The Warrants, sold at $0.1875 per share, have an exercise price of $1.25 per share, are immediately exercisable, and will expire five years from issuance. ProMIS anticipates gross proceeds from the PIPE financing, combined with proceeds from the exercise of existing warrants, to total approximately $12.0 million. The funds will be utilized to advance the clinical development of PMN310, the company's lead therapeutic candidate, and for working capital and general corporate expenses. The financing is expected to close soon, pending customary closing conditions.